pharmaphorum

APRIL 1, 2021

The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, building on a first approval last year. The median progression free survival (PFS) for Sarclisa combination therapy was not reached at the time of the pre-planned interim analysis, the company said.

Adverse Reactions 54

Adverse Reactions Labelling Chemotherapy 54

Pharmaceutical Technology

JANUARY 12, 2023

It has been approved to treat NSCLC patients with EGFR Exon20 insertion mutations, whose disease has advanced on or after they received platinum-based chemotherapy. Rash, decreased appetite, paronychia, and diarrhoea are the most common adverse reactions (TRAEs) related to the treatment.

Adverse Reactions 52

Adverse Reactions Chemotherapy 52

LifeProNow

MAY 8, 2023

The standard therapy for these patients consists of intensive salvage immunochemotherapy followed by high-dose chemotherapy and HSCT for those whose disease responds to the salvage therapy and are eligible for transplant.

Chemotherapy 130

Chemotherapy Adverse Reactions 130

pharmaphorum

JANUARY 26, 2022

It covers three phase 3 trials involving subjects with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), as well as ‘unfit’ AML patients who are unable to be treated with intensive treatment like high-dose chemotherapy.

Adverse Reactions 40

Adverse Reactions Chemotherapy Immunity Immunization 40

LifeProNow

APRIL 30, 2023

Adverse Reactions (ARs): In the data from the four randomized placebo-controlled trials, the most common ARs (≥ 10%) that occurred more frequently (≥ 2% over placebo) in XTANDI-treated patients were asthenia/fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite, diarrhea, and hypertension.

Adverse Reactions 130

Adverse Reactions Chemotherapy Diabetes 130

Pharmaceutical Technology

NOVEMBER 9, 2022

The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals ’ PD-1 inhibitor Libtayo (cemiplimab-rwlc) and chemotherapy combination as the first-line treatment for advanced non-small cell lung cancer (NSCLC). The regulatory approval is based on results obtained from the international Phase III EMPOWER-Lung 3 trial.

Chemotherapy 52

Chemotherapy Adverse Reactions 52

Pharmaceutical Technology

NOVEMBER 23, 2022

Libtayo is also indicated for treating progression of the disease on or following platinum-based chemotherapy. The trial enrolled 608 subjects in 14 countries, regardless of their PD-L1 expression status or histology and assessed Libtayo versus a chemotherapy of investigator's choice.

Adverse Reactions 52

Adverse Reactions Chemotherapy Immunity Immunization 52

Pharmaceutical Technology

FEBRUARY 5, 2023

The FDA approval is based on the data obtained from a global, multicentre, open-label Phase III TROPiCS-02 study conducted in 543 HR+/HER2- metastatic breast cancer patients who have received prior endocrine therapy, CDK4/6 inhibitor and two to four lines of chemotherapy for metastatic disease. Trodelvy showed 3.2

Adverse Reactions 105

Adverse Reactions Chemotherapy Labelling 105

LifeProNow

APRIL 19, 2023

The product is intended for use in adults and pediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation or chemotherapy). director of the FDA’s Center for Biologics Evaluation and Research.

Adverse Reactions 130

Adverse Reactions Chemotherapy Labelling Immunity 130

Pharmaceutical Technology

MARCH 23, 2023

Zynyz monotherapy showed a 52% objective response rate (ORR) in chemotherapy-naïve patients. Diarrhoea, rash, pyrexia, nausea, musculoskeletal pain, fatigue and pruritus are the most common adverse reactions observed in patients treated with Zynyz. Partial response was seen in 22 patients and complete response in 12 patients.

Adverse Reactions 98

Adverse Reactions Compounding Chemotherapy Labelling 98

pharmaphorum

APRIL 14, 2021

Trodelvy (sacituzumab govitecan) has been approved for locally advanced or metastatic urothelial cancer, following a platinum-containing chemotherapy and PD-1/PD-L1 inhibitor immunotherapy. Adverse reactions leading to treatment discontinuation occurred in 10% of those receiving Trodelvy, with 4% discontinuing treatment due to neutropenia.

Adverse Reactions 52

Adverse Reactions Chemotherapy 52

European Pharmaceutical Review

NOVEMBER 24, 2022

s Libtayo ® (cemiplimab) for adults with recurrent or metastatic cervical cancer and disease progression while on or after platinum-based chemotherapy. “Libtayo ® was the first programmed cell death protein (PD)-1 inhibitor to demonstrate significant improvements in survival compared to chemotherapy in a Phase III trial.

Chemotherapy 86

Chemotherapy Immunity Immunization Adverse Reactions 86

Pharmaceutical Technology

MAY 22, 2023

As a non-chemotherapy, single-agent treatment for DLBCL patients, we hope that Epkinly can effectively treat this aggressive cancer type and can be used for patient care quickly and in an off-the-shelf form for physicians. The FDA approval of Epkinly represents a new treatment mechanism of action for third-line DLBCL patients. “As

Adverse Reactions 52

Adverse Reactions Chemotherapy 52

The Thyroid Pharmacist

SEPTEMBER 1, 2023

They include anesthetics, antacids, anti-anxiety medications, antibiotics, antidepressants, antifungals, cholesterol-lowering medications, anti-malarial medications, chemotherapy, appetite suppressants, arthritis medications, psychotropics, and steroids. Who is Likely to Have an Adverse Reaction to Fluoride, and What are the Symptoms?

Adverse Reactions 115

Adverse Reactions Compounding Chemotherapy Labelling 115

LifeProNow

APRIL 19, 2023

Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ABECMA treatment, and until immune recovery following treatment with ABECMA. The safety of immunization with live viral vaccines during or after ABECMA treatment has not been studied.

Adverse Reactions 100

Adverse Reactions Vaccines Immunity Immunization 100

RX Note

FEBRUARY 23, 2023

G6PD Deficiency - Explaining G6PD Deficiency Ramadan - Medications during Ramadan fasting Adverse Drug Reactions Adverse Drug Reactions - All adverse reactions are adverse drug event Pharmacovigilance - To detect unreported ADRs Drug Allergy - Management vary based on the signs and symptoms Medicine-induced Discolouration - Red?

HIV Treatment and Prevention Agents 75

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 75

European Pharmaceutical Review

DECEMBER 27, 2023

Bridging therapy has been shown to correlate with an inferior response to CAR T-cell therapy due to both progression of the chemotherapy-refractory malignant disease during the manufacturing period and increased toxicity. After this incident CAR-related toxicity scales and guidelines were established to prevent adverse reactions.

Adverse Reactions 83

Adverse Reactions Immunity Immunization Medical Schools 83

The Thyroid Pharmacist

JULY 8, 2022

It’s important to note that selenium may also interact with other supplements and medications, such as cholesterol-lowering statin drugs, antacids, chemotherapy drugs, corticosteroids, niacin, and even birth control pills. At high enough levels, selenium can cause death (reports of this level of toxicity exist, but are extremely rare). (58,

Dosage 59

Dosage Immunity Immunization Diabetes 59